Summary We analysed ploidy and S-phase fraction (SPF) from 78 paraffin-embedded primary prostatic carcinomas by DNA flow cytometry. DNA aneuploidy and above median (4.2%) SPF were both associated with high tumour grade, large size of prostate and presence of distant metastases. Both aneuploidy and high SPF (>4.2%) indicated short 10-year progression-free (P = 0.01 for ploidy and P = 0.0002 for SPF), overall (P = 0.004 and P <0.0001) as well as prostate cancer survival (P = 0.002 and P <0.0001). Ten-year overall survival rate was 45% in cases with SPF below 4.2% and 0% in those with higher values, whereas the corresponding prostate cancer-specific survival rates were 80% and 11%, respectively. None of the seven tumours with SPF above 12% showed an objective response to endocrine therapy, whereas 26/49 (52%) of those with lower SPF values responded (P = 0.01). DNA ploidy, tumour grade, T-stage or M-stage did not significantly correlate with endocrine responsiveness. SPF was also the best predictor of progression free survival in patients treated hormonally. In conclusion, dletection of high SPF in prostate cancer may indicate lack of hormonal responsiveness and poor prognosis.
Analysis of tumour DNA ploidy and S-phase fraction (SPF) by flow cytometry has been shown to provide additional independent information to prognostic assessment in a variety of malignancies (Merkel & McGuire, 1990; Hedley, 1989) . Several studies indicate that prostate cancer patients with DNA-aneuploid tumours have shorter disease-free and overall survival than those with DNA-diploid tumours (Fordham et al., 1986; Lee et al., 1988; Montgomery et al., 1990; Nativ et al., 1989; Stephenson et al., 1987; Winkler et al., 1988) . However, it is still controversial whether aneuploidy is an independent prognostic indicator. At least four groups have reported DNA aneuploidy to be an additional prognostic factor in prostate cancer (Adolfsson et al., 1990 ; Montgomery et al., 1990; Nativ et al., 1989; Stephenson et al., 1987) , whereas some other investigators have failed to detect any independent value for aneuploidy after correcting for the effect of other prognostic indicators (Detjer et al., 1989; Haugen & Mjolner6d, 1990; Ritchie et al., 1988) .
Few investigators have studied SPF from prostatic carcinomas. SPF appears to be higher in carcinomas than in benign prostate lesions (Schultz et al., 1985) as well as in poorly differentiated carcinomas as compared to welldifferentiated ones (Neill et al., 1989) . SPF has also been found to be higher in DNA-aneuploid tumours than in DNA diploid ones (Frankfurt et al., 1984) . However, the actual prognostic value of SPF in prostate cancer has remained unknown. In the present study we compared the significance of tumour DNA ploidy and SPF in the assessment of longterm prognosis and responsiveness to endocrine therapy in 78 primary prostatic carcinoma patients. A new software program was used to more accurately analyse SPFs from DNA histograms obtained from paraffin-embedded tissues (Kallioniemi et al., 1991) .
Materials and methods

Patients
The material consisted of 78 previously untreated histologically confirmed primary prostatic carcinomas diagnosed at the Tampere University Central Hospital during [1977] [1978] [1979] . The patients were staged using the TNM classification as recommended by UICC (UICC, 1987 (Mostofi, 1980) . Fifty micrometer sections were cut from corresponding paraffin-embedded blocks. The sections were dewaxed using a modification of Hedley's method (Hedley et al., 1983) was evidence of nuclear aggregation as indicated by the presence of a peak in the hexaploid region. We have chosen 15% as a cut-off limit since this limit has been systematically used in our laboratory for the analysis of other human malignancies. Our experience indicates that if cell cycle distributions are calculated from cell populations (like small tetraploid peaks) accounting for less than 15% of the total cell count, the interference by nuclear debris and aggregates makes the analysis very unreliable.
Cell cycle distribution was analysed using the Multicycle software program (Phoenix Flow Systems, San Diego, CA).
Most of the paraffin-embedded tumours produced a DNA histogram with a predominantly flat debris distribution on the left side of the diploid GO/GI peak. This debris is mostly caused by cleaved nuclei that are produced during specimen preparation (Kallioniemi et al., 1991) . The MultiCycle software models the background debris by assuming a random probability of any nucleus being cut into random-sized fragments during sample processing. The background signals are then numerically eliminated from the DNA histogram on a channel-by-channel basis. Any residual excess background at low histogram channels is fitted by a power function. After debris subtraction a zero-order Dean and Jett (Dean & Jett, 1974) model for cell cycle analysis was used. In aneuploid cases only the cell cycle of the aneuploid clone was registered.
Interference caused by the S-and G2/M-phase cells of the diploid clone was accounted for either by modelling two proliferating cell cycles or by excluding the G2/M peak of the diploid clone from the analysis using a specific software option. SPF was considered inevaluable in four cases.
Statistical analysis
Statistical analyses of the clinicopathological and survival data were done using the BMDP Statistical Software Package (Dixon, 1981) . The significance of survival differences between patient groups was evaluated using the Mantel-Cox test (BMDP1L (Table I ). The incidence of aneuploidy also tended to be higher in locally advanced tumours (stages T3-T4) and in tumours from older patients, but these trends did not reach statistical significance.
Median SPF of all 74 evaluable tumours was 4.2% with a mean of 6.4 ± 5.8% (± s.d.). DNA-aneuploid tumours had a higher SPF value (10.7 ± 7.2%) than DNA-diploid ones (3.9 ± 2.7%). High SPF was associated with poorly differentiated high-grade tumours, large size of prostate, locally advanced tumours (T3-T4) and the presence of distant metastases (MI) ( Table I ). There was also a trend for SPF to be higher in tumours from older patients.
Progression-free survival rate was shorter in patients with DNA-aneuploid tumours in comparison to those with DNAdiploid ones (Figure la) . The same difference was observed in overall survival rates (Figure lb) . After correcting for intercurrent deaths the significance of this difference increased further (Figure 1c) . The relative risk of tumour progression or patient death was about two times higher in DNA-aneuploid than in DNA-diploid cases. Patients with tetraploid tumours (DNA index 1.80-2.20) did not have significantly different survival as those with other types of aneuploidy.
SPF turned out to be a better prognostic factor than DNA ploidy. Using the median SPF (4.2%) as a cut-off value, prostate cancer patients with high SPF had a significantly shorter progression-free survival (Figure 2a ), overall survival ( Figure 2b ) and survival corrected for intercurrent deaths (Figure 2c ) as those with a low SPF. Ten-year survival rate corrected for intercurrent deaths in cases with below median SPF was 80% as compared with 11% in those with above median SPF. According to a univariate Cox regression analysis this difference was equivalent to a risk ratio of about 7.5. Overall survival rates of patients with below and above median SPF were 45% and 0%, respectively.
To further evaluate the prognostic value of SPF a stratified analysis was carried out using survival corrected for intercurrent deaths as the end-point (Table II) . SPF had a higher prognostic impact in DNA-diploid than in DNA-aneuploid cases. Patients with distant metastases (Ml) could not be subdivided according to SPF into different prognostic categories, whereas in cases without distant metastases at the time of diagnoses (MO) SPF was a strong prognostic factor. An association between high SPF and poor prognosis was also detected among the well (grade I) and moderately (grade II) differentiated tumours. SPF did not have additional prognostic value in grade III tumours as virtually all these cases had a high SPF value. High SPF (>12%)  7  100  0  0  Grade I   14  58  10  42  Grade II   12  48  13  52  Grade III  7  64  4  36  T1 and 2  10  55  8  45  T3  11   58  8  42  T4  11  52  1 0  48  MO  20  54  17  46   M1   12  55  10  45 aPearson chi-square P =0.0110. 0 DNA ploidy, which also previously has been found to predict disease outcome (Fordham et al., 1986; Haugen & Mjolnerod, 1990; Lee et al., 1988; Montgomery et al., 1990; Nativ et al., 1989; Stephenson et al., 1987; Winkler et al., 1988) , SPF had a stronger impact and provided additional information on prognosis both among the DNA-diploid and DNA-aneuploid groups. Previously, only two small studies have been published on SPF analysis by flow cytometry in prostate cancer (Neill et al., 1989; Frankfurt et al., 1984) . These publications did not include follow-up studies. They reported a correlation between SPF and DNA ploidy as well as between SPF and tumour grade, which we also were able to confirm in the present larger series. Insensitivity to primary endocrine therapy was characteristic to a small subgroup of cases with very high (> 12%) SPF levels. No other tumour parameter including ploidy, grade or stage correlated significantly with the degree of hormonal response. It is generally recognised that the prediction of responsiveness to endocrine therapy is difficult in prostate cancer (Schultze & Isaacs, 1986) . On the basis of in vitro studies of prostate cancer cell lines it appears that a major factor contributing to endocrine responsiveness is the presence on a functional androgen receptor (Horoszewicz et al., 1983) . Although androgen receptor negative tumour cells have been described by immunocytochemistry (Demura et al., 1988) , there is no direct evidence of a correlation between steroid receptor status of prostate tumours and clinical response rates. It remains to be determined, whether the absence of a measurable hormonal response in the rapidly proliferating tumours is specifically due to the lack of androgen-mediated growth regulation and/or activation of alternative growth promoting mechanisms (Morris & Dodd, 1990) . Tumour grade did not predict endocrine responsiveness suggesting that the effect of SPF was probably not related to the loss of differentiation of tumour cells. It Analysis of SPF by flow cytometry from tumours in general, and from paraffin-embedded material in particular, has been criticised due to lack of accuracy and reproducibility (Vindelov & Christensen, 1990) . However, DNA flow cytometry remains the best method available to access archival material and determine proliferation status of tumours from patients followed clinically for many years (Hedley, 1989) . Futhermore, recent progress in the development of sophisticated computer models has made it possible to overcome some of the shortcomings in the methodology. It is nowadays possible to effectively discriminate the aneuploid SPF from overlapping diploid cell cycle as well as compensate for nuclear debris overlying the SPF in DNA histograms. We have recently demonstrated that the prognostic value of SPF is improved by subtracting the debris signals using a 'sliced nuclei' model that effectively eliminates most of the debris from archival tumour tissues underlying in DNA histograms (Kallioniemi et al., 1991) . We could reproducibly analyse cell cycle distributions from as many as 95% of the DNA histograms considered evaluable for DNA ploidy, which makes it unlikely that a selection bias could have affected our comparison of SPF and DNA ploidy as prognostic indicators (Hedley et al., 1987) .
However, it should be recognised that in DNA-diploid tumours it is still not possible to discriminate the cell cycle of tumour cells from that of stromal and inflammatory cells that are projected on the same channels in the DNA histogram. In the present study we tried to prepare tumour-rich areas from paraffin blocks for flow cytometric analysis. Since SPF values had better prognostic value in the DNA-diploid than in the DNA-aneuploid cases it is likely that at least the presence of an elevated SPF value in DNA-diploid tumours should be taken into account. Furthermore a correlation has been reported between flow cytometric SPF and 3H-thymidine labelling index (McDiwitt et al., 1986) as well as between SPF and expression of proliferation antigens (Dawson et al., 1990) .
Our results indicate that determination of tumour cell proliferation by flow cytometric SPF analysis reflects the inherent biological aggressiveness and therapy responsiveness of prostatic carcinomas. Analysis of tumour proliferation rate may in the near future play a major role in improving prognostic and therapeutic assessments of patients. Although the subgroups that most likely would benefit from the analysis are not yet known, determination of tumour proliferation rate should be incorporated into randomised clinical trials on prostate cancer therapy. 
